Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 585-591

  Toth, Peter P ^a,b   Grabner, Michael ^c   Punekar, Rajeshwari S ^c   Quimbo, Ralph A ^c   Cziraky, Mark J ^c   Jacobson, Terry A ^d  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c HEALTHCORE INC   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Cardiovascular disease prevention; CHD; Comparative effectiveness; Health services research; LDL C; LDL P; Lipoproteins; MESA; Outcomes; PH; Risk factors; T2DM

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN PARTICLE; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DEMOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; AGED; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; CORONARY DISEASE; MIDDLE AGED; PARTICLE SIZE; RISK FACTOR; STROKE; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; RISK FACTORS; STROKE; UNITED STATES;

EID: 84907801969     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.914     Document Type: Article

References (26)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAm Med Assoc 2001, 285:2486-2497.
2. Sniderman A.D., Lawler P.R., Williams K., Thanassoulis G., deGraaf J., Furberg C.D. The causal exposure model of vascular disease. Clin Sci 2012, 122:369-373.
3. Sniderman A., Kwiterovich P.O. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes 2013, 20:140-147.
4. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
5. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. JAm Coll Cardiol 2013 Nov 7, pii: S0735-1097(13)06028-2. [Epub ahead of print]. 10.1016/j.jacc.2013.11.002.
6. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
7. Cromwell W.C., Barringer T.A. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009, 11:468-475.
8. Otvos J.D., Jeyarajah E.J., Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22i-29i.
9. Cromwell W.C., Otvos J.D. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 2006, 98:1599-1602.
10. Rosenson R.S., Davidson M.H., Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic risk. Atherosclerosis 2010, 213:1-7.
11. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk for future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. JClin Lipidol 2007, 1:2458-2464.
12. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
13. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. JClin Lipidol 2011, 5:105-113.
14. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013, 19(Suppl.1):1-48.
15. Davidson M.H., Ballantyne C.M., Jacobson T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. JClin Lipidol 2011, 5:338-367.
16. Contois J.H., McConnell J.P., Sethi A.A., et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009, 55:407-419.
17. Cole T.G., Contois J.H., Csako G., et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC lipoprotein and vascular diseases division working group on best practices. Clin Chem 2013, 59:1-19.
18. Quan H., Li B., Couris C.M., et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011, 173(6):676-682.
19. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70(1):41-55.
20. D'Agostino R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17(19):2265-2281.
21. Kurth T., Walker A.M., Glynn R.J., et al. Results of multivariate logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006, 163(3):262-270.
22. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL-cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012, 14:1-10.
23. Rosenson R.S., Underberg J.A. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther 2013, 10.1007/s10557-013-6477-6.
24. Rosenson R.S., Otvos J.D., Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome. Diabetes Care 2009, 32:1087-1091.
25. Sniderman A.D. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. JClin Lipidol 2008, 2:36-42.
26. Rizzo J.A., Mallow J.P., Waters H.C., Pokrywka G.S. Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effectiveness analysis. JClin Lipidol 2013 Nov-Dec, 7(6):642-652.